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Abstract 
Destruction of the established tumour vasculature by a class of compound termed Vascular 
Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the 
management of solid tumours. VDAs induce a rapid shutdown and collapse of tumour blood 
vessels, leading to ischaemia and consequent necrosis of the tumour mass. Their efficacy is 
hindered by the persistence of a viable rim of tumour cells, supported by the peripheral 
normal vasculature, necessitating their co-administration with additional chemotherapeutics 
for maximal therapeutic benefit. However, a major limitation for the use of many cancer 
therapeutics is the development of life-threatening cardiovascular toxicities, with significant 
consequences for treatment response and the patient’s quality of life. The aim of this review 
is to outline VDAs as a cancer therapeutic approach and define the mechanistic basis of 
cardiovascular toxicities of current chemotherapeutics, with the overall objective of 
discussing whether VDA combinations with specific chemotherapeutic classes would be good 
or bad in terms of cardiovascular toxicity. 
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1. Introduction. 
Increased understanding of the molecular basis of cancer over the past decade has advanced 
cancer chemotherapy into an era of “targeted molecular therapeutics” alongside 
“conventional cytotoxic agents” (Collins & Workman, 2006; Weinstein & Joe, 2006). However, 
despite many of these medicines significantly improving cancer treatment and patient 
survival, it is now clear that their benefit is counterbalanced by adverse toxic effects, 
particularly upon the cardiovascular system (Alameddine et al., 2015; Dy & Adjei, 2013; Raschi 
et al., 2010; Tocchetti et al., 2013). Consequently, challenges exist with respect to identifying, 
managing or at least monitoring cancer-therapy related cardiovascular toxicity, to provide the 
most beneficial cancer treatment, ultimately improving patient outcomes and longer-term 
healthcare. A task and activity which led to the emergence of cardioncology as a defined 
discipline (Ky et al., 2013; Todaro et al., 2013). In order to administer safer yet still effective 
cancer treatments, a much greater appreciation of the underlying molecular mechanisms by 
which current therapies cause adverse effects upon the cardiovascular system and how to 
predict these toxicities before they arise in the clinic is essential. 
In terms of clinical presentation, chemotherapy-induced cardiotoxicity is classified 
into three types: symptomatic acute toxicity occurring soon after administration, and early- 
and late-onset chronic toxicity, occurring before or after one year of treatment, respectively 
(Bagnes et al., 2010; Curigliano et al., 2010; Yeh, 2006). Due to the often asymptomatic nature 
of acute cardiotoxicity, which presents as rhythm disturbances, transient reductions in 
myocardial contractility, and/or hypotension, and the fact that it is reversible by 
discontinuation of treatment, this adverse effect is commonly under recognised. The 
infrequency of this cardiotoxicity subtype does not equate to it being inconsequential or 
irrelevant; as sub-clinical adverse effects may contribute to cumulative cardiac damage or 
asymptomatic loss of cardiac function. In the case of early- and late-onset chronic progressive 
cardiotoxicities, these are associated with electrophysiological changes and left ventricular 
dysfunction, which presents clinically as irreversible cardiomyopathy (Curigliano et al., 2012).  
With late-onset chronic progressive cardiotoxicity, the deterioration in cardiac function is 
progressive over many years and can be as long as one to two decades after completion of 
cancer therapy. 
Chemotherapy-induced toxicity, although commonly manifesting as an effect upon 
the cardiac system, also poses a risk to the coronary and peripheral vascular systems, through 
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exacerbation of hypertension, perturbations in vascular tone, or direct vascular damage 
(Herrmann et al., 2016). Alongside cardiac toxicity, this obviously has an effect upon the 
circulatory cardiovascular system and indirectly upon the heart itself. Several 
chemotherapeutic drugs, most notably the molecular targeted kinase inhibitors, have been 
shown to induce vascular toxicity in the clinic (Herrmann et al., 2016; Touyz et al., 2018). 
However, unlike the recent cross-disciplinary awareness of chemotherapy-induced 
cardiotoxicity, vascular toxicity per se is still largely under-appreciated in the clinic and 
strategies targeted towards its mitigation and management are not fully defined. 
Nevertheless, chemotherapy-induced effects upon the vascular system remain important and 
directly pertinent to cancer management and cardioncology. 
Cardiovascular toxicity is without doubt a long-term complicating factor in cancer 
treatment, from asymptomatic electrocardiographic perturbations through to symptomatic 
life-threatening events such as heart failure, appearing both acutely and taking several years 
to manifest (Cardinale et al., 2016; Salvatorelli et al., 2015; Todaro et al., 2013). Despite this, 
the severity and life-threatening nature of cancer in conjunction with the improvement in 
overall survival associated with treatment often outweighs these toxicological safety risks 
(Salvatorelli et al., 2015; Todaro et al., 2013).  
 
2. Tumour vasculature as a therapeutic target in cancer 
Tumour growth and expansion, invasive capacity and ultimately metastasis and dissemination 
to other parts of the body, are all hugely dependent upon a functioning vascular network 
(Tozer et al., 2005; Weis & Cheresh, 2011). The absence or failure of a tumour to sustain a 
viable blood flow causes a restriction in growth and cessation of progression due to lack of 
nutrition and oxygen, and build-up of metabolic waste products and carbon dioxide (Tozer et 
al., 2005). Similarly, the inability or prevention of a tumour to develop new blood and 
lymphatic vessels (angiogenesis and lymphangiogenesis) causes a restriction in growth 
volume to a few millimetres and concomitant tumour dormancy (Weis & Cheresh, 2011). 
Consequently, targeting of the vasculature within tumours has significant potential for 
therapeutic intervention (Ji et al., 2015; Tozer et al., 2005; Weis & Cheresh, 2011), with 
strategies broadly categorised into two areas; i) inhibition or interference in the development 
and recruitment of a new vascular supply to the tumour with consequent stasis of tumour 
expansion, through perturbation of the angiogenic process (Weis & Cheresh, 2011), and ii) 
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disruption and collapse of the existing tumour vasculature, resulting in ‘tumour starvation’, 
and consequent tumour necrosis and death (Ji et al., 2015; Tozer et al., 2005) (see Figure 1).  
 The former of these areas, the anti-angiogenesis therapeutic strategy, has seen an 
explosion of interest over the past ‘molecular therapeutic’ decade and has resulted in 
advancement of agents in this class into the clinic with significant success (Shahi & Pineda, 
2008; Weis & Cheresh, 2011). The majority of these anti-angiogenic therapeutics are 
concerned with blockade of vascular endothelial growth factor (VEGF) activity within the 
tumour, through either sequestering circulating VEGF, blockade of the VEGF-receptor, or 
disruption of the intracellular signalling pathway (Weis & Cheresh, 2011). It is now clearly 
evident that these anti-angiogenic therapies exhibit a significant adverse effect upon the 
cardiovascular system, particularly hypertension and heart failure (Alameddine et al., 2015; 
Cameron et al., 2016; Ky et al., 2013; Tocchetti et al., 2013; Vasiliadis et al., 2014). This is 
briefly discussed later in this review. 
 In contrast to anti-angiogenic approaches which prevent neo-vasculature 
development, the vascular-disrupting strategy for cancer treatment is focused on affecting 
the ‘established’ vasculature within the tumour (see Figure 1). In ‘normal’ non-tumorous 
tissue, the vasculature architecture is organised into regular structures, with mature 
endothelial cells forming a defined lumen supported by a well-established network of 
pericytes and smooth muscle cells (Baluk et al., 2005; Barlow et al., 2013; Siemann et al., 
2017; van Dijk et al., 2015). In contrast, as a consequence of the rapid and relatively 
uncoordinated nature of their development, tumour vascular networks are particularly 
unorganised and formless, with random irrational vessel connections and chaotic blood flow 
(Baluk et al., 2005; Barlow et al., 2013; Siemann et al., 2017). Furthermore, tumour 
vasculature is actively growing and lacks control mechanisms that are protective to blood flow 
normalcy (Baluk et al., 2005; Barlow et al., 2013; Deryugina & Quigley, 2015). The differential 
in vasculature structure and blood flow across the tumour, the rapid growth and concomitant 
dependency on a supportive blood supply, and the immaturity of the endothelial cells within 
the tumour therefore exposes the validity of targeting vascular supply to limit and inhibit 
tumour growth, survival, and dissemination. Consequently, selectively disrupting the 
established blood supply to tumours is now known to be an effective therapeutic strategy, 
with several vascular disrupting agents (VDAs) targeting the colchicine-binding domain of β-
tubulin currently in preclinical development or late stage clinical trial (Ji et al., 2015; Mason 
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et al., 2011), as shown in Table 1. The underlying mechanism as to why these agents have 
such a profound effect on tumour over “normal” blood vessels has yet to be conclusively 
proven clinically. However, there is compelling preclinical information to suggest that the 
demands of the tumour and its environment presents the tumour endothelial cells with an 
abnormal cellular physiology, such that their immaturity results in their rigidity and shape 
being dependent upon an intracellular tubulin cytoskeleton rather than the largely actin 
cytoskeleton present in mature established endothelial cells and blood vessels (Furst & 
Vollmar, 2013; Kanthou & Tozer, 2009; S. Kim et al., 2012; Mahal et al., 2015; Schwartz, 2009). 
Consequently, agents which disrupt tubulin dynamics would have a profound effect on 
tumour endothelial cell structure, with minimal effects to endothelial cells in mature blood 
vessels. Furthermore, it is now well established that the disruption of a single tumour blood 
vessel results in death of the large number of tumour cells it supports (Kanthou & Tozer, 2007; 
Mita et al., 2013; Tozer et al., 2005). Additionally, the destabilization of the tumour 
endothelium leads to a temporal enhancement of vascular permeability and consequent drug 
retention, with significant potential for therapeutic enhancement (Mason et al., 2011; Reyes-
Aldasoro et al., 2008; Tozer et al., 2005).  
 VDAs offer several positive therapeutic attributes relative to the majority of cancer 
therapeutics. Firstly, they are not required to extravasate from the blood vessel and penetrate 
across several cell layers for their activity and thus are not hindered by intra-tumoural 
pharmacokinetic dilution. Secondly, they target a fundamental process for survival of all solid 
tumours and therefore have widespread potential, through affecting ‘non-tumorigenic cells’ 
within the tumour microenvironment avoiding undesirable acquired drug resistance 
associated with genomic instability of malignant cells (Kanthou & Tozer, 2007; Lippert, 2007; 
Mita et al., 2013). Despite exhibiting significant potential, it is becoming increasingly apparent 
that the therapeutic value for these colchicine-related VDAs is compromised by their intrinsic 
toxicity, including cardiac toxicities (Chase et al., 2017; Hinnen & Eskens, 2007; Ho et al., 2017; 
Mita et al., 2013; Siemann et al., 2009; Subbiah et al., 2011) 
 
2.1 Cardiotoxicity of Vascular Disrupting Agents 
Several preclinical in vivo laboratory investigations and clinical trials have been performed to 
evaluate toxicity of the tubulin-interactive VDAs (Beerepoot et al., 2006; Hinnen & Eskens, 
2007; Ho et al., 2017; Sessa et al., 2013; Subbiah et al., 2011; Tozer et al., 2005). In several 
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cases VDAs have been shown to cause a wide range of detrimental effects upon the 
cardiovascular system (Table 2) (Hinnen & Eskens, 2007; Ho et al., 2017; Siemann et al., 2009; 
Subbiah et al., 2011). 
 Preclinical studies of cardiac effects of the tubulin-binding VDAs, ZD6126 and the 
combretastatin family of anticancer drug, were performed in rats, involving continuous 
monitoring of both heart rate and blood pressure alongside histopathological and 
biochemical analyses (Anderson et al., 2003; Gould et al., 2007; Grosios et al., 1999; Jaroch et 
al., 2016; P. M. LoRusso et al., 2008; Rustin et al., 2010; Subbiah et al., 2011; Tochinai et al., 
2016; Zweifel et al., 2011).  Administration of ZD6126 was associated with high levels of 
circulating troponin T (clinical biomarker of cardiac toxicity) in the blood and drug-induced 
delayed tachycardia and hypertension (Gould et al., 2007). In the case of combretastatin-A4-
phosphate (CA4P) and its analogue combretastatin-A4-disodium-phosphate (CA4DP), drug-
induced increases in mean arterial blood pressure were also observed. However, no 
detectable increases in troponin were observed (Ke et al., 2009). Interestingly, pre-
administration of calcium channel blockers prevented hypertension induced by both ZD6126 
and combretastatins in these rat models (Gould et al., 2007; Ke et al., 2015), offering the 
notion that VDA-related elevated blood pressures maybe linked to increased peripheral 
vessel resistance (Anderson et al., 2003; Grisham et al., 2018). 
In clinical trials, several cardiotoxic effects were detected within a few hours of 
administration of ZD6126, including abnormal cardiac function, pain or pressure in the mid-
chest region or left arm, and increased systemic levels of the biomarker of cardiotoxicity 
troponin (Beerepoot et al., 2006). Although CA4P is tolerated better than ZD6126 and other 
VDAs, its use is still accompanied by a range of cardiac adverse effects. The most common 
adverse effect of CA4P is an acute transient increase in baseline blood pressure, wherein a 
10-15% increase above baseline is observed within one hour of administration, with normal 
state returning within 3-4 hours post-infusion (Grisham et al., 2018). Drug-induced 
tachycardia and contradictory bradycardia are both evident with CA4P therapy; typically 
characterised by a decrease in heart rate (bradycardia) within the first hour post-infusion 
followed by an increase (tachycardia) around 3-4 hours later, and a return to baseline by 24 
hours (Grisham et al., 2018; Rustin et al., 2003; Zweifel et al., 2011). Several patients receiving 
CA4P have also experienced myocardial ischaemia, although in the majority of cases an 
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underlying confounding issue was identified, such as coronary artery disease (Garon et al., 
2016; Grisham et al., 2018; Rustin et al., 2003; Sosa et al., 2014). 
In terms of clinical management of CA4P-induced cardiac effects, a treatment 
algorithm was devised for use in the phase II FOCUS trial (CA4P in combination with the anti-
angiogenic agent bevacizumab and cytotoxic chemotherapy) involving differential strategies 
for patients presenting with hypertension and those normotensive (Monk et al., 2016). 
Patients with hypertension were managed through optimisation of their current medication, 
and in those patients without established hypertension an evaluation of cardiovascular risk 
factors was undertaken prior to receiving CA4P (Grisham et al., 2018; Monk et al., 2016). High-
risk patients were those with any previous CA4P-induced blood pressure effect or with 
baseline blood pressure >130 mmHg, and the presence of cardiovascular risk factors 
(diabetes, previous myocardial infarction, prior uncontrolled hypertension etc.). A major risk 
factor of pertinence for cancer therapy was also receipt of prior anthracyclines, an issue which 
will be appraised later in this review. However, in all cases, frequent monitoring of blood 
pressure after CA4P administration was deemed essential to mitigate the acute CA4P-induced 
cardiac complications (Grisham et al., 2018; Monk et al., 2016). 
 
2.2. Necessity for use of VDAs in combination therapy. 
Despite showing significant potential as a potent therapeutic strategy for the management of 
many solid cancers, the major limitation of VDAs are their inability to significantly affect those 
cells at the periphery of the tumour mass, in the so-called “viable tumour rim” (see Figure 1). 
(Blakey et al., 2002; Tozer et al., 2005). As such, the endothelial cells of these established 
blood vessels no longer rely on the tubulin cytoskeleton for their structure, but rather a more 
well-established cytoskeletal structure underpinned by actin and other such fibres, with 
consequences for the success of VDAs (Tozer et al., 2005). Furthermore, blood vessels located 
within the tumour periphery are associated with a high density of supporting pericytes, 
known to play an important role in microvascular stabilisation and hypothesised to contribute 
to the resistance to VDAs in this region (Chen et al., 2017; Tozer et al., 2008). 
 Consequently, clinical administration of a VDA will need to be accompanied with a 
therapeutic to effectively target these persistent cells, most notably a cytotoxic therapeutic 
(Table 1). In contrast to this being perceived negatively, the reality is actually the converse 
with the two-pronged approach likely to be more successful and efficacious than either 
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therapeutic alone. It is well known that a major limitation to current cancer treatment is the 
limited activity of ‘standard’ chemotherapeutics against those tumour cells towards the 
centre of the mass because of diffusional limitations (Minchinton & Tannock, 2006). The dual 
VDA and cytotoxic approach would effectively overcome this limitation, with the VDA 
destroying those ‘hard-to-reach’ cancer cells from mid-tumour towards periphery (via 
shutdown of tumour blood vessels), and the cytotoxic chemotherapeutic destroying the VDA-
resistant cells of the tumour viable rim. As described recently by Song et al., the VDA serves 
as a “cannon” eradicating many tumour cells without the requirement to interact with them, 
whereas the conventional cytotoxic chemotherapeutic concomitantly serves as a “pawn” by 
killing tumour cells in close proximity to blood vessels and within the drugs diffusional 
parameters (Song et al., 2016). With this co-administration strategy there is potential that 
drug doses may also be lower due to a lack of necessity to inherently compensate for 
difficulties in drug penetration. Furthermore, the inherent activity of VDAs to collapse tumour 
blood vessels has the added benefit of also entrapping drugs within the tumour mass and 
retarding their diffusion away from this site. Such an approach has been exemplified by the 
recently identified tumour-activated VDA, ICT2588 (Atkinson et al., 2010; Gill et al., 2014). 
 With regards combination therapy with VDAs, there are several chemotherapeutic 
classes which could be used, each with their advantages and disadvantages in terms of 
cardiovascular toxicities (Table 1). Several of these therapeutics are discussed in this context 
below. 
 
2.2.1. Potential and risk for co-administration of VDAs and conventional chemotherapeutics 
The fact that VDAs need to be administered concomitantly with therapeutics to tackle the 
“viable rim” of the tumour introduces several confounding factors to their putative success, 
not least the significantly elevated risk of additive or synergistic deleterious effects upon 
normal body systems. As clearly demonstrated in this review, cardiotoxicity is an issue 
associated with the vast majority of conventional chemotherapeutics and the VDAs. In 
essence cardiotoxicity induced by cancer therapeutics is a consequence of either direct 
cytotoxicity to cardiomyocytes (and other cardiac cell types, such as fibroblasts and pericytes) 
and the limited regenerative capacity therein, drug-induced perturbations of cardiac 
excitation-contraction coupling, induction of structural cellular changes and hypertrophic 
responses, effects upon the wider cardiovascular system, or combinations of these. This 
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thereby raises the question as to whether co-administration of VDAs and conventional 
chemotherapeutics is wise and the risk manageable. 
 
2.2.2 Benefits of vascular disruption for co-administration of chemotherapeutics 
As is the case with all of the ‘standard’ cytotoxic chemotherapies, strategies which modify, 
reduce, or limit exposure of the cardiovascular system to the detrimental agents, whilst 
maintaining high enough drug levels to deliver therapeutic efficacy against the cancer is an 
idealistic target. The cannon and pawn approach (Song et al., 2016) precipitates the need for 
any concomitant chemotherapy to focus specifically on the viable tumour rim and not be 
hindered by modification of doses to facilitate efficacious drug levels throughout the tumour. 
In essence this would equate to systemic delivery of lower but highly efficacious 
concentrations of toxic chemotherapeutic, thereby reducing cardiac drug exposures. 
 Targeting of the viable rim by chemotherapeutics, ideally at modified concentrations, 
necessitates careful consideration of the administration schedules and the actual mechanism 
of the additional therapeutic agent (Fruytier et al., 2016; Martinelli et al., 2007). The vast 
majority of studies to date support administration of the VDA prior to the chemotherapeutic, 
causing a reduced requirement for the chemotherapeutic to reach the tumour ‘core’ and 
exclusively target the viable tumour rim. The outcome is heavily dependent upon the degree 
of effect the VDA has upon the tumour, and the microenvironmental changes secondary to 
VDA-induced blood flow (Fruytier et al., 2016). Of pertinence to cardiovascular toxicities of 
combination therapy, the intervals between the two therapeutics is believed to be highly 
important with strong potential for crossover of acute toxicity profiles. 
 Several studies have now also suggested that the effects of the additional 
chemotherapeutic could be further potentiated through the VDA-mediated ‘trapping’ of the 
drug within the tumour, resulting in increased tumour drug exposures (Atkinson et al., 2010; 
Martinelli et al., 2007; Siemann, 2011). Such a mechanism would be seen as beneficial in 
terms of cardiotoxicity, through reduction in systemic drug levels and modulation of 
pharmacokinetics and subsequent cardiac exposure levels. However, despite offering 
significant potential from a cardiovascular toxicity mitigation perspective, the VDA-mediated 
trapping of the chemotherapeutic could have both positive and negative connotations for 
therapeutic efficacy. These responses are multifactorial and dependent upon both of the 
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drugs that are administered and their dosing schedules. The significance of this for 
cardiovascular toxicity is as yet unknown. 
 
3. Cardiovascular toxicity of alkylating agents 
Alkylating agents, which bind DNA and inhibit its replication, have widespread application in 
cancer treatment (Todd et al., 2017). The archetypal nitrogen mustard alkylating agents, 
cyclophosphamide and its structural analogue ifosfamide, are generally well tolerated at 
lower doses. However, in many cases, high-dose regimens are required and this is commonly 
associated with presentation of acute cardiotoxicity (Curigliano et al., 2012; Yeh & Bickford, 
2009). Symptomatically this presents within two weeks post-administration as a combination 
of cardiac affects, including arrhythmias, left ventricular dysfunction, and congestive heart 
failure, with considerable morbidity and mortality reported (Curigliano et al., 2012). To date, 
there are no significant cases reported of longer term or late-stage chronic cardiotoxicity with 
cyclophosphamide or ifosfamide. The mechanisms responsible for acute cardiotoxicity 
remain unconfirmed, but are postulated to be a consequence of direct endothelial damage, 
extravasation of the drug and subsequent toxicity against cardiomyocytes, intracapillary 
microemboli and ultimately cardiac ischaemia (Curigliano et al., 2012; Jones & Ewer, 2006). 
Consequently, cardiotoxicity in the case of cyclophosphamide and ifosfamide is accepted as 
being due to administration of high-dose therapy rather than as a result of cumulative 
therapeutic dose, and thus theoretically could be reduced through modification of dosing 
regimens. 
Platinum containing alkylating agents, specifically cisplatin and its analogues 
carboplatin and oxaliplatin, form inter-and intra-strand crosslinks with DNA, and are often 
administered alongside other chemotherapeutic drug classes. In contrast to the nitrogen 
mustard alkylating agents, cisplatin treatment is associated with dose-limiting acute and 
cumulative cardiovascular toxicity. Platinum-induced acute cardiotoxic events include 
abnormalities of ventricular repolarisation, depressed contractility, myocarditis, 
thromboembolic events, and dysrhythmias (Oun & Rowan, 2017; Patane, 2014; Yeh & 
Bickford, 2009). Although the mechanism underpinning platinum-induced acute 
cardiotoxicity is not fully resolved, it is hypothesised to be a consequence of direct damage of 
the vascular endothelium, induction of oxidative stress and a prothrombic state, and 
platinum-driven mitochondrial ultrastructural abnormalities and cellular stress  (Altena et al., 
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2011; El-Awady el et al., 2011; Patane, 2014). Additional to acute cardiotoxic effects, cisplatin 
is also associated with delayed cardiotoxicity and increased risk for myocardial infarction over 
subsequent years (Gietema et al., 2000; Meinardi et al., 2000; Patane, 2014), with cisplatin 
detectable in urine and blood plasma  twenty years after treatment (Gerl & Schierl, 2000; 
Gietema et al., 2000). 
 
3.1 Co-administration of VDAs and alkylating agents 
The nitrogen mustard class of alkylating agent in combination with a VDA does not appear to 
have been appraised either preclinically or in clinical trials (see table 1). In light of the severity 
of reported cardiotoxicities and the types of malignancy currently managed by these agents 
it is understandable why such a combination has not yet been evaluated. However, the 
potential for dose reduction as a consequence of VDA effects and focused targeting of the 
viable tumour rim is an intriguing concept. 
 With regards to platinum-containing alkylating agents, despite associations with both 
acute and cumulative cardiotoxicity, several studies have evaluated this class of agent 
alongside VDAs (Table 1). In preclinical studies, VDAs delivered concomitantly with platinum 
alkylating agents resulted in significant synergistic antitumour effects (Ma et al., 2012; 
Takahashi et al., 2016). In the majority of cases, translation of this into clinical trials reinforced 
the synergistic efficacy, with no evidence of extensive dose-limiting cardiovascular toxicities 
(Grossmann et al., 2012; Lickliter et al., 2010; Ma et al., 2012; Takahashi et al., 2016). Overall, 
the toxicity of VDAs in the presence and absence of platinum-containing chemotherapeutics 
was particularly consistent with VDA monotherapy, with a few exceptions (Blay et al., 2015). 
Although somewhat surprising that cardiovascular toxicities of platinum-containing drugs 
were not more prevalent when in combination with a VDA, it remains to be determined 
whether combination with a VDA modifies the risks of cisplatin-mediated delayed 
cardiotoxicity over subsequent years (Patane, 2014). 
 
4. Cardiovascular toxicity of antimetabolites  
The antimetabolite class of chemotherapeutic either mimic or prevent the cellular synthesis 
of nucleotides, required for the synthesis of DNA, exemplified by the pyrimidine antagonist 
cytarabine and the fluoropyrimidine 5-fluorouracil (5-FU)(Todd et al., 2017). Although 
generally well tolerated, these drugs can induce a spectrum of adverse cardiovascular effects, 
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including vascular effects such as angina, hyper- and hypo-tension, heart failure, and cardiac 
effects including arrhythmias, cardiogenic shock and myocardial infarction (Brana & 
Tabernero, 2010; Depetris et al., 2018; Herrmann et al., 2016). The incidence of drug-induced 
cardiovascular toxicity is highly variable across studies, made worse by continuous infusion, 
concurrent treatment with other drugs, or co-existing cardiac disease (Depetris et al., 2018; 
Polk et al., 2013). From a mechanistic perspective, the pathogenesis of cardiovascular toxicity 
is not yet resolved, with vasoconstriction being the main candidate, supported by endothelial 
damage, impairment of the antioxidant defence system, oxidative stress, and direct 
myocardial damage (Depetris et al., 2018; Herrmann et al., 2016).  
 
4.1 Co-administration of VDAs and antimetabolites 
To date there are no reports describing clinical administration of a VDA and either 5-FU or 
capecitabine (the prodrug of 5-FU). Although a study has evaluated Oxi4503 co-
administration with cytarabine (Table 1), this was against leukaemia and thus Oxi4503 in this 
case would not have been acting as a VDA (Watts et al., 2017). Nevertheless, no indication of 
additional drug-induced cardiotoxicity was reported (Watts et al., 2017). In light of the 
exiguity and controversy in data surrounding the mechanistic basis of cardiovascular toxicity 
of the antimetabolites it is difficult to postulate or extrapolate the risk and benefits for co-
administration of VDAs with these agents. 
  
5. Cardiovascular toxicity of drugs disrupting topoisomerase activity 
Topoisomerase type I (TOPI) and type II (TOPII) enzymes are ubiquitously expressed in 
mammalian cells, wherein they function to modulate DNA coiling and structure permissive of 
DNA replication, transcription, and chromosome organisation, via either single or double 
strand breaks, respectively (Delgado et al., 2018; Todd et al., 2017). Topoisomerase-targeted 
drugs are exquisitely selective, as TOPI poisons do not affect TOPII and vice versa, and they 
function as poisons rather than catalytic inhibitors, culminating in the induction of DNA 
damage and cell death (Delgado et al., 2018; Nitiss, 2009; Pommier, 2013). Administration of 
drugs targeted at topoisomerases is associated with development of secondary malignancies 
(Delgado et al., 2018; Pendleton et al., 2014) and cardiovascular toxicity (Delgado et al., 2018), 
the latter of which is of major significance for VDA co-administration and is detailed below. 
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5.1 Topoisomerase I targeted agents 
Targeting topoisomerase I (TOPI) is a proven strategy for management of a number of 
malignancies, with semisynthetic camptothecin derivatives, topotecan and irinotecan, 
approved for clinical use (Delgado et al., 2018; Martino et al., 2017). The incidence of 
cardiovascular toxicity with these agents is extremely rare, with no reported cases of 
topotecan-induced cardiovascular toxicity, and only an isolated case of irinotecan-induced 
bradycardia reported in the literature (Miya et al., 1998). To date, no chronic cardiovascular 
toxicities of these drugs has been reported either. This lack of apparent cardiovascular toxicity 
may purely be a consequence of reduced life expectancy or limited numbers of patients 
receiving these therapies, or simplistically the fact that no study has yet appraised longer-
term toxicity follow-up of this patient population. 
 
5.1.1 Co-administration of VDAs and topoisomerase I poisons 
Current evidence would suggest that combination with VDAs would not precipitate any 
additional risk of cardiotoxicity. However, the potential to administer lower doses of TOPI-
targeted drugs would negate impact of their short drug half-lives, and would theoretically 
reduce dose-limiting toxicities and permit curative doses to be delivered. Although, 
limitations due to chemical instability and inherent resistance of tumours to this class of agent 
would impact upon the overall VDA co-administrative strategy. 
 
5.2 Topoisomerase II targeted agents 
Drugs targeting TOPII are the commonest cytotoxic treatment used in the clinic for the 
management of a wide-range of adult and paediatric malignancies (Todd et al., 2017). 
Clinically-approved TOPII drugs affect the activities of both TOPIIα and TOPIIβ and encompass 
the anthracyclines (e.g. doxorubicin, epirubicin and daunorubicin), etoposide, and 
mitoxantrone (Delgado et al., 2018; Nitiss, 2009; Pommier, 2013). However, despite these 
therapeutics being potent and widely used cancer therapeutics, their use is undeniably 
associated with detrimental effects upon the cardiac system and significant concerns are now 
being raised regarding the aftermath of chemotherapeutic-treatment. 
 Anthracyclines are the mainstay of many cancer treatment regimes, with doxorubicin 
being the most commonly used. The major risk factor for development of doxorubicin-
induced cardiac dysfunction is now known to be the cumulative drug exposure, with the 
Page 17 of 45 
 
incidence of clinical heart failure with doxorubicin treatment is reported to rise exponentially 
from 5% with a cumulative dose of 400 mg/m2 to 48% with 700 mg/m2 (Henriksen, 2018). The 
risk is further increased in older patients, when given as a component of multi-modality or 
multi-agent therapeutic approaches (Jiang et al., 2018; Lotrionte et al., 2013). However, 
despite limiting total cumulative doxorubicin exposure to 450 mg/m2 resulting in less acute 
cardiovascular toxicity events, no significant reduction in late-onset complications has been 
reported, implicating that no dose of doxorubicin is inherently safe for the cardiovascular 
system (Cappetta et al., 2018; Lipshultz et al., 2005). Therefore, although cumulative dose is 
inherently related to development of cardiovascular toxicity, several other contributory 
factors are now known to be involved, including dosing rate and schedule, patient age, female 
gender, hypertension, previous cardiovascular disease, and genetic predisposition (Brana & 
Tabernero, 2010; Cappetta et al., 2018; Lipshultz et al., 2013; Lotrionte et al., 2013). 
There are several hypotheses proposed to explain the mechanistic basis for 
doxorubicin-induced cardiotoxicity, including iron-mediated generation of reactive free 
radicals, specific interactions with TOPIIβ, drug-induced mitochondrial dysfunction, and 
perturbation of mitochondrial topoisomerase (mTOP) activity (Cappetta et al., 2017; Cappetta 
et al., 2018; Khiati et al., 2014; Octavia et al., 2012; Piegari et al., 2013; Renu et al., 2018; 
Vejpongsa & Yeh, 2014). Although it is highly likely these effects are not exclusive and that 
multiple mechanisms drive anthracycline-induced cardiotoxicity. 
Similar to anthracyclines, the anthraquinone mitoxantrone (MTX) also induces 
cumulative and dose-dependent cardiotoxicity, somewhat unsurprising in light of the fact that 
mitoxantrone was developed as a synthetic doxorubicin analogue, albeit supposedly with 
decreased cardiotoxicity (Damiani et al., 2016). Although cardiotoxicity was initially 
reportedly lower for mitoxantrone relative to doxorubicin, a recent paediatric study indicates 
the contrary with mitoxantrone being associated with a higher risk for late-stage 
cardiotoxicity than doxorubicin (Feijen et al., 2019). Nevertheless, it is likely that the mode of 
cardiotoxic action of mitoxantrone and the anthracyclines is similar (Damiani et al., 2016). 
 In contrast to mitoxantrone and anthracyclines, etoposide shows minimum or no 
cardiovascular toxicity and very rarely drug-induced arrhythmias (Airey et al., 1995; Dorigo et 
al., 1993; Escoto et al., 2010; Kridis et al., 2013). However, etoposide has been associated with 
development of vasospastic angina, hypotension and myocardial infarction, implying a 
vascular toxicity risk for this drug (Airey et al., 1995; Escoto et al., 2010; Schwarzer et al., 1991; 
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Yano & Shimada, 1996). Effects upon atrial electroconductivity are also reported when 
etoposide is given in combination with the alkylating agent cisplatin (Kucharz et al., 2016). In 
most cases, it is highly likely that cardiovascular toxicities associated with etoposide are 
synergistic with or caused by the concomitant medications rather than other predisposing 
factors.  
 
5.2.1 Co-administration of VDAs and topoisomerase II targeted agents 
The co-administration of VDAs and the widely used anthracyclines has not yet been appraised 
clinically (Table 1). However, this combination offers significant therapeutic potential from an 
oncological standpoint, as indicated preclinically in sarcoma (Atkinson et al., 2010; Gill et al., 
2014) and colon tumours (Song et al., 2016).  
 In terms of oncology chemotherapy, anthracyclines are exquisitely associated with 
cardiovascular toxicity, with both acute and chronic effects well documented. It is without 
doubt that the cumulative dose of anthracyclines is the major issue to address in terms of 
longer term adverse and life-threatening effects. The potential offered by VDAs to reduce 
overall anthracycline exposure as a consequence of necessity to just target the tumour cells 
within the post-VDA viable tumour rim, rather than penetrate deep into the tumour, is 
therefore attractive. Such a strategy and strong support for this is evidenced in the study of 
the VDA prodrug ICT2588 alongside doxorubicin, wherein lower doses of doxorubicin were 
shown to be efficacious and relevant (Atkinson et al., 2010; Gill et al., 2014). If translated to 
the clinic, a highly likely prospect, this would also result in a reduction in total exposure levels 
to the anthracycline (and mitoxantrone), the main factor behind the significant cardiovascular 
toxicity of this class of compound. 
 The inherent low risk of etoposide-induced cardiovascular toxicity would support its 
therapeutic use alongside VDAs. Interestingly, preclinical studies have shown that repeated 
low-dose etoposide treatment impairs the angiogenic potential of endothelial cells, 
associated with increased sensitivity to vascular-disrupting effects of chemotherapy (Pasquier 
et al., 2013). Therefore, despite its individual ‘cardiac safety profile’, etoposide may have an 
extra benefit in that it could further reduce any VDA-induced cardiovascular toxicity. 
Improved understanding of these mechanisms, their clinical validity and significance is 
thereby warranted in order to mitigate for the risk of VDA-etoposide treatment regimens. 
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6. Cardiovascular toxicity of microtubule binding agents: Taxanes 
Taxanes are used widely in the treatment of breast, ovarian and non-small cell lung cancers, 
wherein they exert their action by binding to microtubules and promoting their 
polymerisation and inactivation, culminating in mitotic arrest and cell death (Todd et al., 
2017). Cardiac complications of these agents, specifically paclitaxel and docetaxel, include 
arrhythmias and cardiac ischaemia. The most common effect of these drugs upon the heart 
is transient sinus bradycardia, occurring in approximately one-third of patients during 
infusion, as a consequence of a direct chronotropic effects upon the Purkinje system. Drug-
induced cardiac ischaemia is also reported for the taxanes, occurring in 5% and 2% of patients 
with paclitaxel and docetaxel, respectively (Rowinsky et al., 1991), However, unlike 
bradycardia which is a direct effect, taxane-induced ischaemia is associated with established 
cardiac disease. Notably, taxane-mediated  heart failure is particularly associated with 
patients receiving prior anthracycline therapy (Sessa & Pagani, 2001), delaying the catabolism 
of anthracyclines and causing a greater reduction in the left ventricular ejection fraction 
(Minotti et al., 2001). The formulation of taxanes into Cremaphor EL, a polyoxyethylated 
castor oil vehicle, is also proposed to contribute to their cardiovascular toxicity, as it is 
recognised to stimulate histamine release and thus hypothesised to increase myocardial 
oxygen demand, coronary vasoconstriction, and changes in cardiac chronotrophy 
(Gelderblom et al., 2001). 
 
6.1. Co-administration of VDAs and taxanes 
Several studies have appraised VDAs alongside taxanes, notably docetaxel or paclitaxel (Table 
1). In clinical trials appraising ABT-751 and docetaxel against advanced prostate cancer there 
were no clinically evident cardiovascular adverse events associated with treatment (Michels 
et al., 2010), with the caveat that cardiac function was not formally assessed in these trials. 
Similarly, fosbretabulin (CA4P) in combination with carboplatin and paclitaxel in advanced 
cancer patients did not result in any significant adverse cardiac effects, above those expected 
for each drug alone (Garon et al., 2016; Rustin et al., 2010; Zweifel et al., 2011). 
Combination treatment of ombrabulin (AVE8062) and docetaxel was deemed superior 
to either agent alone in preclinical studies (Eskens et al., 2014; Nishio et al., 2018). In clinical 
trials of ombrabulin and docetaxel, no indication of additional chronic or delayed toxicities 
were observed (Eskens et al., 2014; Sessa et al., 2013). This included an absence of cardiac 
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ischaemia, cardiac decompensation, drug-induced dysrhythmias, or cardiac biomarker 
abnormalities, and no promotion of hypertension in patients with a hypertensive history. In 
contrast to these initial studies, a recent trial of ombrabulin and docetaxel conducted in 
Japanese patients did report development of severe dose-limiting toxicities, although none 
were attributed to cardiovascular events (Nishio et al., 2018). The study claimed docetaxel 
clearance was reduced by co-administration of ombrabulin, with subsequently increased 
prevalence of taxane-mediated toxicities (Nishio et al., 2018).  
To date, no negative associations have been reported between VDAs and taxanes in 
terms of the cardiovascular system in clinical studies, with the implication that no cardiac 
restrictions or limitations are required for their co-administration (Eskens et al., 2014). In 
addition, the VDA-facilitated potential for reduction in administered taxane dose also has 
beneficial potential for reducing the adverse cardiac effects observed with taxanes alone 
(Minotti et al., 2001; Rowinsky et al., 1991; Sessa & Pagani, 2001) 
 
7. Cardiovascular toxicity of microtubule binding agents: Vinca alkaloids 
Targeting and disruption of tubulin function is a successful and efficacious strategy for cancer 
therapy across many tumour types (Todd et al., 2017). The vinca alkaloids (Vincristine, 
Vinblastine and analogues) bind to cellular microtubules, similar to taxanes and colchicine-
like VDAs, albeit it at different binding sites (Todd et al., 2017). In contrast to microtubule 
stabilisation induced by taxanes, these drugs depolymerise and destabilise the mitotic 
spindle, ultimately resulting in cell cycle arrest and cell death (Coderch et al., 2012; Martino 
et al., 2018).  
Cardiovascular toxicity caused by vinca alkaloids is primarily vaso-restrictive in nature, 
including angina, hypertension, myocardial ischaemia and myocardial infarction (Floyd et al., 
2005).  Alongside reversibility in drug-induced ECG perturbations, vinca-induced coronary 
spasm and subsequent cardiac ischaemia are rationalised as the driver for cardiovascular 
toxicities of this class of cancer chemotherapeutic (Herrmann et al., 2016). Such a theory is 
reinforced by a reported increased risk of ischaemic complications with vinca alkaloid 
administration in patients with established coronary artery disease (Herrmann et al., 2016). 
 
7.1. Co-administration of VDAs and vinca alkaloids 
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There are no reports in the literature detailing clinical administration of a VDA and a vinca 
alkaloid, and subsequently no clinical reports describing toxicities of co-administration. 
However, a recent preclinical study against hepatocellular carcinoma showed that 
administration of fosbretabulin alongside vincristine resulted in an augmented therapeutic 
effect relative to either agent alone in vivo (Aboubakr et al., 2017). Although effects upon the 
cardiovascular system were not specifically evaluated, increased vascular effects and elevated  
levels of reactive oxygen species, were measurable within the wider hepatic environment 
(Aboubakr et al., 2017). This highlights questions regarding their safe clinical use in 
combination.  
The potential for administration of lower doses of a vinca alkaloid, due to the 
mechanistic activity of the VDA, provides scope to improve clinical efficacy and theoretically 
reduce dose-limiting toxicities of this drug class. However, a potential caveat to co-
administration is that both drug classes function to destabilise microtubule dynamics (as 
opposed to the taxanes), albeit through different mechanisms (Coderch et al., 2012). 
Although the similarity of therapeutic mechanism could affect therapeutic efficacy, especially 
in light of genomic instability and acquisition of drug resistance, it is unlikely to play a major 
role in off-target effects against normal tissues. 
 
 8. Molecular targeted therapies 
The most recent efforts in anti-cancer therapeutics have been toward the development of 
molecular targeted therapies. The theory behind this effort is that by making cancer 
therapeutics more targeted, inhibiting specific molecular targets instead of generalised DNA 
interaction, some of the toxicities seen with conventional cytotoxic chemotherapeutics could 
be eliminated or at least ameliorated.  This unfortunately has not been the case for many 
chemotherapy-related toxicities, cardiovascular toxicity included. Many of these molecular-
targeted agents have demonstrated adverse effects upon the heart, from mild 
electrophysiological changes, to myocarditis and fatal heart failure (Bellinger et al., 2015; 
Varricchi, Galdiero, & Tocchetti, 2017). The rationale for co-administration of these agents 
with VDAs in order to target the viable tumour rim is not evidentially strong. The 
cardiovascular toxicity mechanisms of these molecular-targeted agents is likely diverse, but 
is largely outside the scope of this review and is extensively addressed elsewhere (Bellinger 
et al., 2015; Florido et al., 2017; Rhea & Oliveira, 2018; Varricchi, Galdiero, & Tocchetti, 2017). 
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However, therapeutic approaches of relevance and interest for co-administration with VDAs 
are briefly described below. 
 
8.1 Anti-angiogenic agents 
Tumour growth, invasion, dissemination and overall survival are dependent upon the 
existence of a viable and functional vascular and lymphatic network, which develop from the 
host vasculature via the angiogenic process (Tozer et al., 2005; Weis & Cheresh, 2011). There 
are now several strategies proposed for the targeting and interference of the angiogenesis 
process and thus prevention of tumour expansion and dissemination. The most notable 
strategies being sequestering vascular endothelial growth factor (VEGF) and prevention of its 
binding to the cell-surface receptor VEGFR (e.g. the monoclonal antibody bevacizumab), and 
inhibition of downstream signalling from VEGFR and other similar receptors (e.g. the tyrosine 
kinase inhibitors such as axitinib, pazopanib, sorafenib, and sunitinib) (Weis & Cheresh, 2011). 
Not surprisingly, many of the anti-angiogenic drugs have reported close relationships to 
cardiovascular toxicity, both asymptomatically and symptomatically, with hypertension being 
a major issue with both VEGF-sequestering and kinase inhibitor classes of these agents 
(Faruque et al., 2014). Although not yet conclusively proven, it is highly likely that these 
cardiovascular toxicities are a result of direct effects upon the vasculature and subsequent 
hypertension, cardiac strain and heart failure, in conjunction with effects upon the renal 
system (Cosmai et al., 2015; Di Lorenzo et al., 2009). Such a hypothesis is supported by the 
fact that cardiovascular toxicity induced by these agents is higher in patients with pre-existing 
cardiovascular risk factors (Chu et al., 2007; Di Lorenzo et al., 2009; Grisham et al., 2018; Rhea 
& Oliveira, 2018). 
 
8.1.1 Co-administration of VDAs and anti-angiogenic agents 
Despite anti-angiogenic agents and VDAs both hitting tumour vasculature, their marked 
differences in mechanism and target offers the opportunity for a two-pronged attack on the 
tumour and a different therapeutic approach (Siemann et al., 2017). Simplistically, this 
strategy rationale is to destroy existing vasculature and concomitantly prevent the 
development of new supportive blood vessels requested by the tumour, which as a minimum 
would be cytostatic for the tumour and retard any further tumour growth. Additional to the 
mechanistic differences, the anti-angiogenic also serves to prevent revascularisation during 
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and after treatment with the VDA (Siemann et al., 2017). However, as is the case with VDAs, 
anti-angiogenic monotherapy is highly unlikely to be curative even when given at high doses 
or for a prolonged period of time. Similarly, although combination therapy offers promise, 
with the VDA targeting the tumour core and antiangiogenic therapy inhibiting 
neovascularisation, the viable tumour rim is still highly likely to survive. Consequently, these 
therapies are suggested to be positioned as maintenance therapy in patients previously 
administered other chemotherapeutics, with the objective of improving progression free 
survival (Fabi et al., 2012; Siemann et al., 2017) 
 Several preclinical studies have indicated a marked improvement in tumour response 
for co-administration of an anti-angiogenic drug and a VDA, relative to either agent alone 
(Siemann et al., 2017). These results and others subsequently led to several clinical trials 
evaluating the archetypical anti-angiogenic angtibody bevacizumab (Avastin) alongside a VDA 
(table 1). For the vast majority of studies, this dual anti-vascular approach was well tolerated 
and improvements in progression free survival were observed (Siemann et al., 2017). In a 
phase II clinical trial in chemotherapy-naiive lung cancer, fosbretabulin in combination with 
bevacizumab, carboplatin (alkylating agent), and paclitaxel (antimicrotubule agent) similar 
drug-induced adverse events were observed between all treatment groups. No differences in 
serious adverse events or early discontinuations from the trial were observed between groups 
receiving CA4P and those not (Garon et al., 2016; Siemann et al., 2017). Of note in all reported 
studies to date of bevacizumab and a VDA is the fact that hypertension is the most common 
dose-limiting toxicity, albeit of an increased magnitude than bevacizumab alone (Grisham et 
al., 2018; Nathan et al., 2012). Whilst bevacizumab primarily causes sustained hypertension 
requiring modulation of hypertensive medication, the elevated blood pressure observed with 
the VDA is acute and managed with either pre-treatment or immediate administration of 
hypertensive medication at the time of initial blood pressure rise (Grisham et al., 2018). 
Despite several trials demonstrating promising and encouraging results for co-administration 
of a VDA and bevacizumab, it remains to be determined whether this treatment regimen is 
optimal in terms of efficacy, or whether assessment on a wider patient population would 
identify further issues. 
 Although several studies have appraised bevacizumab combination therapy 
with VDAs, few studies have evaluated VDAs alongside small molecule VEGF-signalling 
pathway inhibitors. In preclinical studies, the VDA BNC105 potentiates the activity of 
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pazopanib against renal cancer (Inglis et al., 2014) and co-administration of OXi4503 and 
sunitinib results in improved efficacy against colorectal liver metastasis (Nguyen et al., 2016). 
In both studies no obvious clinical signs of cardiotoxicity were observed. Recently, this 
treatment approach has been translated to the clinic as a phase 1b/II trial of fosbretabulin 
and pazopanib against ovarian cancer (Morgan et al., 2018). However, although improved 
therapeutic efficacy was indicated, several patients developed acute hypertension plus 
secondary cardiac toxicity, resulting in premature discontinuation of the trial (Morgan et al., 
2018). Further studies are therefore required to characterise the mechanistic basis of this 
unacceptable toxicity, and ascertain the cardiotoxicity safety profile of combination 
treatment with VDAs and anti-angiogenic approaches. Consequently, until further refined and 
understood, the detrimental cardiotoxic risk of these agents is likely to preclude their use in 
combination therapies with VDAs. 
 
8.2 Cardiovascular toxicity of immune checkpoint inhibitors and implications for VDA co-
treatment 
In addition to the development of therapeutics activating or inactivating signalling 
pathways, in response to defined mutations (i.e.  molecular-targeted therapies), advances in 
molecular immunology unveiling the mechanisms driving cellular immune response have now 
led to a new class of therapeutic termed immune checkpoint inhibitors (Sharma & Allison, 
2015a, 2015b). These therapeutic antibodies, targeting either cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand (PD-L1), have 
demonstrated excellent clinical success against a diverse range of malignancies (Sharma & 
Allison, 2015a; Varricchi, Galdiero, Marone, et al., 2017). However, the downside to the high-
ranking success of immune checkpoint inhibitors is their wide-spectrum of immune-related 
adverse effects, including effects upon the heart (Varricchi, Galdiero, Marone, et al., 2017; 
Varricchi, Galdiero, & Tocchetti, 2017). In particular, immune checkpoint inhibitors have been 
shown to cause myocarditis and fatal heart failure, both when administered alone and in 
combination with other therapeutics (Varricchi, Galdiero, Marone, et al., 2017; Varricchi, 
Galdiero, & Tocchetti, 2017).  
The co-administration of immune checkpoint inhibitors alongside VDAs has been 
proposed as a strategy to improve treatment success and VDA efficacy, with the rationale that 
the VDA will damage tumour blood vessels and encourage lymphocytic infiltration and 
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subsequent tumour destruction (Inglis et al., 2016; Missiaen et al., 2018). The Australasian 
MODULATE clinical trial, initiated in early 2019, is investigating whether a VDA (BNC105) in 
combination with an immunotherapeutic agent (nivolumab) can be used to treat advanced 
colorectal cancer. Based on the emerging novel cardiotoxicty profile of immune checkpoint 
inhibitors and hypertensive response associated with VDAs, outcomes from this combination 
study are eagerly awaited. 
 
9. Conclusion: VDAs and cancer therapy, good or bad in terms of cardiovascular toxicity? 
The potential for VDAs as a viable therapeutic option for the treatment of solid tumours has 
been clearly qualified by numerous preclinical studies and early stage clinical trials. From a 
therapeutic perspective, despite demonstrating clear promise, the existence of a viable rim 
of tumour cells following VDA monotherapy thereby means the clinical efficacy of VDAs are 
dependent upon co-administration of an additional chemotherapeutic agent to target these 
surviving tumour cells. Although such a treatment model has demonstrated exquisite 
preclinical therapeutic effects, including tumour eradication and the potential for dose 
reduction of chemotherapeutics, the potential for exacerbating off-target cardiovascular 
toxicity of cancer therapeutics was raised as a concern. 
 Detrimental effects upon the cardiovascular system are a common occurrence across 
the diverse spectrum of cancer chemotherapeutics. Effects upon the cardiac system itself and 
the wider vasculature are evident, ranging from overt toxicity and structural cardiac changes, 
to alterations in cardiac contractility and the development of drug-induced dysrhythmias, 
through to induction of vascular contractility and subsequent haemodynamic changes. In the 
case of VDAs, the most prevalent cardiovascular effect is acute haemodynamic change 
occurring immediately after administration, with resolution within the subsequent following 
few hours. On the whole, cardiovascular effects of VDAs are generally transient and 
manageable with standard cardiac medication, and with frequent monitoring of blood 
pressure whilst receiving VDA therapy. Consequently, VDA-induced cardiovascular toxicity 
per se is not deemed a hidden evil, but rather a manageable risk. The complication arises 
when the VDA is administered alongside a chemotherapeutic which itself exhibits detrimental 
effects upon the heart, with the cardiovascular toxicity effects of each agent potentially 
multiplying each other. Although each class of chemotherapeutic with potential for VDA co-
administration exhibits slightly different risk, as described above, in several cases this is a 
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consequence of delivery of high-dose (e.g. alkylating agents) or cumulative dose (e.g. 
anthracyclines). In principle, these toxicities may be mitigated when delivered alongside a 
VDA wherein a lower dose of the cytotoxic chemotherapeutic agent may be possible due to 
the requirement to only ‘hit’ those cells in the viable tumour rim. 
The vast majority of  cardiotoxic effects observed with cancer chemotherapeutics are 
reportedly acute or early onset in nature, with their identification and subsequent 
management easier to identify and plan. However, as is evident with anthracyclines, drug-
induced cardiotoxicity in some cases may present several years after administration. This is 
problematic in that cardiac damage and effects remain ‘silent’ and only present as fairly late 
stage cardiac failure. The emergence of these delayed toxicities is a consequence of significant 
improvements in cancer therapy and the consequent prolongation in patient survival. It 
remains to be ascertained whether non-anthracycline chemotherapy classes, including VDAs, 
also associate with delayed cardiotoxicity. Furthermore, whether combination therapy of 
VDAs and chemotherapeutics promote or retard delayed and late-stage cardiotoxicity can as 
yet not be predicted. The occurrence of these delayed effects will only become evident 
through increases in patient survival and subsequent clinical presentation of cardiological 
effects, at which point it maybe too late to prevent or reverse these effects. Therefore, a 
deeper understanding and appreciation of the off-target effects of such therapies and 
molecular mechanisms will be essential to predicting and potentially treating cardiovascular 
toxicities of all cancer chemotherapeutic approaches, including VDAs. 
One factor appearing as a constant aggravator of cardiovascular toxicity, especially in 
the case of detrimental effects upon the vascular system, is pre-existing cardiac disease. 
Clinical use of many cancer chemotherapeutics are strongly avoided in patients with cardiac 
comorbidities or coronary artery disease, unless the benefit exceeds the risk. It is therefore 
assumed that such a restriction would also be applicable to VDAs, not least because of the 
requirement for co-administration of additional chemotherapeutics. The caveat being that 
the effects of VDA upon the vasculature system appear to be transient in nature and occur 
across a short post-administration window. If effects of VDAs are manageable in this context, 
then the beneficial effects of lowering exposure to the additional chemotherapeutic may 
serve to circumvent the issues associated with treatment in this patient population. 
The emergence of molecular-targeted therapies heralding a new wave of successes in 
terms of clinical efficacy of cancer is encouraging. The manageability of hypertensive effects 
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associated with combination of VDAs with the anti-angiogenic agent bevacizumab is obviously 
very promising (Garon et al., 2016; Grisham et al., 2018; Siemann et al., 2017). However, 
unlike bevacizumab, the fact that trials of pazopanib in combination with fosbretabulin were 
prematurely terminated due to cardiac toxicities raises the concern regarding adoption and 
qualification of drug-specific versus therapeutic-pathway approaches for VDA combination 
therapy (Morgan et al., 2018). Similarly, in the context of molecular-targeted approaches, the 
severity of cardiotoxic effects caused by immune checkpoint inhibitors (Varricchi, Galdiero, 
Marone, et al., 2017) questions their suitability for combination with VDAs, a point that may 
be resolved once the outcomes of the MODULATE trial of BNC105 and nivolumab are 
reported. In the meantime, such combinations should be approached with trepidation.  
  
9.1 VDAs and risk of cardiovascular toxicity: Future directions? 
Many issues remain to be resolved with VDAs in respect of their clinical validity for cancer 
management, treatment regimens, and the existence and severity of drug-induced adverse 
cardiovascular effects. In this context, the key issues that need to be addressed are i) the 
contributions played by the cardiac and vascular compartments in VDA-induced 
cardiovascular toxicities, and whether this generic or drug specific in terms of this drug class; 
ii) the true longevity of the haemodynamic effects of VDAs in the clinic and whether clinical 
management strategies, as adopted in the FOCUS trial (Monk et al., 2016), are sufficient to 
mitigate such risk; iii) Clinical studies to date support efficacy of a number of 
chemotherapeutic drugs for co-administration with VDAs in a cannon and pawn approach 
(Song et al., 2016), particularly platinum-containing alkylating agents, anthracyclines and 
taxanes. However, much of this is based on the assumption of effective dose-reduction due 
to VDA presence. Such a hypothesis therefore needs to be robustly addressed in order to 
qualify the potential for these combinations; and finally, iv) the greatest cardiovascular 
problem associated with cancer chemotherapy is delayed cardiotoxicity, appearing many 
years after cessation of treatment. It is therefore imperative that the underpinning 
mechanism for such effects is elucidated to fully appreciate and manage required 
cardiological interventions, with strategies for prediction and mitigation identified. Until such 
queries are addressed it would be difficult to fully assign cardiotoxic risk associations for VDAs 
or their inclusion in combination therapies. However, the evidence relating to effectiveness 
of the tubulin-interactive VDA as a therapeutic approach coupled to lower or manageable 
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cardiotoxic risk is providing compelling arguments towards the incorporation of VDAs as a 
treatment option, albeit hinged upon clinical efficacy. 
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FIGURE 1: 
 
  
Angiogenic factors, predominantly Vascular 
Endothelial Growth Factor (VEGF) and Platelet-
Derived Growth Factor (PDGF), released by 
tumour to stimulate development of new blood 
vessels from established vasculature. 
Anti-angiogenic therapies either prevent 
binding of angiogenic growth factors to 
endothelial cells or inhibit the subsequent 
downstream signalling pathways. This prevents 
tumour expansion and development of tumour 
 
Vascular Disrupting Agents (VDAs) target and 
damage endothelial cells of the immature 
tumour vasculature. This leads to selective 
vascular dysfunction within the tumour mass, 
depriving the tumour of nutrients and oxygen, 
leading to hypoxia, ischaemia and necrosis of 
tumour cells supported by these blood vessels. 
Angiogenesis 
Vascular Disrupting Agent 
e.g. Colchicine 
Anti-angiogenic therapy 
e.g. VEGF-inhibitors 
VDAs do not affect the mature blood vessels at 
tumour periphery. Tumour supported with 
nutrients and oxygen from these established 
vessels are not destroyed by VDA treatment. 
Destruction of cells in this ‘viable rim’ of tumour 
cells thereby requires administration of 
additional cytotoxic or targeted agents. 
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VDA Company Stage of Development Combination Therapies References 
ABT-751* Abbvie Phase II (Multiple cancer types) Pemetrexed (NSCLC); 
Carboplatin (NSCLC); 
Docetaxel (Prostate cancer) 
(Fox et al., 2008; Hande et al., 
2006; Ma et al., 2012; Mauer et 
al., 2008; Michels et al., 2010; 
Rudek et al., 2016; Rudin et al., 
2011; Yee et al., 2005) 
BNC105 / 
BNC105P 
Bionomics Phase I (Multiple cancer types); 
Phase I (CLL); 
Phase II (Renal & colorectal 
cancers); 
Phase II (Mesothelioma) 
Everolimus (Renal Cancer); 
Carboplatin & gemcitabine (Ovarian 
cancer); 
Ibrutinib (CLL); 
Nivolumab (Colorectal cancer) 
(Lindemann et al., 2018; Nowak et 
al., 2013; Pal et al., 2015; Rischin 
et al., 2011) 
CKD-516 
(NOV120401) 
Chong Kun Dang 
Pharmaceutical 
Phase I (Multiple cancer types); 
Phase I/II (Colorectal cancer) 
Irinotecan (Colorectal cancer) (Oh et al., 2016) 
Crolibulin 
(EPC2407) 
Cytovia / 
Immune 
Pharmaceuticals 
Phase II (Thyroid cancer) Cisplatin (Thyroid cancer) (Gramza et al., 2013) 
Denibulin 
(MN-029) 
Medicinova Phase I (Multiple cancer types) None reported to date (Ricart et al., 2011; Traynor et al., 
2010) 
Fosbretabulin 
(CA4P) 
Mateon 
Therapeutics 
(Oxigene) 
Phase I (Multiple cancer types); 
Phase III (Ovarian cancer); 
Phase II (Glioblastoma); 
Phase II (Thyroid cancer); 
Phase II (GI-NETs/PNETs); 
Phase II (Melanoma) 
Carboplatin & paclitaxel (Ovarian 
cancer); 
Bevacizumab (Ovarian cancer); 
Pazopanib (Ovarian cancer); 
Carboplatin, paclitaxel, & 
bevacizumab (NSCLC); 
Carboplatin & paclitaxel (Thyroid 
cancer); 
Everolimus (PNETS); 
Nivolumab (Melanoma) 
 
(Chase et al., 2017; Chauhan, 
Arnold, Dressler, et al., 2018; 
Chauhan, Arnold, Slone, et al., 
2018; Cooney et al., 2004; Garon 
et al., 2016; Grisham et al., 2018; 
He et al., 2011; Libutti et al., 2017; 
Liu et al., 2014; Rustin et al., 2003; 
Sosa et al., 2011; Zweifel et al., 
2011) 
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Lexibulin 
(CYT997) 
Cytopia / YM 
Biosciences 
/Gilead Sciences 
Phase I (Multiple cancer types); 
Phase Ib (Glioblastoma); 
Phase II (Multiple myeloma) 
Carboplatin (Glioblastoma) (Burge et al., 2013; Lickliter et al., 
2010; Lickliter et al., 2008) 
Ombrabulin 
(AVE8062)* 
Sanofi-Aventis Phase I (Multiple cancer types); 
Phase II (NSCLC); 
Phase III (Sarcoma) 
Taxane/Platinum (Multiple solid 
cancer types); 
Cisplatin (Multiple solid cancers); 
Docetaxel (Multiple solid cancers); 
Bevacizumab (Multiple solid 
cancers) 
(Bahleda et al., 2014; Blay et al., 
2015; Conte et al., 2012; Eskens et 
al., 2014; Murakami et al., 2014; 
Nishio et al., 2018; Sessa et al., 
2013; von Pawel et al., 2014) 
Oxi4503 
(CA41P) 
Mateon 
Therapeutics 
(Oxigene) 
Phase I (Multiple cancer types); 
Phase II (Hepatic tumours); 
Phase II (Acute myeloid 
leukaemia) 
Cytarabine (Acute myeloid 
leukaemia) 
(Cogle et al., 2012; Mainwaring et 
al., 2010; Patterson et al., 2007; 
Patterson et al., 2012; Turner et 
al., 2013; Watts et al., 2017) 
Plinabulin 
(NPI-2358) 
BeyondSpring 
Pharmaceuticals 
Phase I/II (Multiple cancer 
types); 
Phase II (NSCLC); 
Phase II (SCLC) 
Docetaxel (NSCLC); 
Nivolumab (Melanoma) 
Nivolumab & ipilimumab (SCLC) 
(Heist et al., 2014; P. LoRusso et 
al., 2007; Millward et al., 2012; 
Millward et al., 2009; Mita et al., 
2010) 
Soblidotin 
(TZT-1027) 
Daiichi Sankyo Phase I (Multiple cancer types); 
Phase II (Sarcoma); 
Phase II (NSCLC) 
Carboplatin (Multiple solid cancers) (de Jonge et al., 2005; Greystoke 
et al., 2006; Horti et al., 2008; 
Patel et al., 2006; Riely et al., 
2007; Tamura et al., 2007; 
Yamamoto et al., 2009) 
Verubulin 
(MPC-6827)  
Myrexis / 
Cytovia  
Phase I (Multiple cancer types); 
Phase I/II (Glioblastoma)  
Carboplatin (Glioblastoma) 
Temozolamide (Glioblastoma) 
(Chamberlain et al., 2014; 
Grossmann et al., 2012; L. J. Kim 
et al., 2011; Zhu et al., 2011) 
ZD6126* Angiogene 
Pharmaceuticals 
Phase II (Multiple cancer types)  Oxaliplatin & 5-Fluorouracil 
(Colorectal Cancer) 
(Beerepoot et al., 2006; P. M. 
LoRusso et al., 2008) 
*Development discontinued 
 
Table 1: Tubulin-targeted VDAs in clinical development   
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VDA-induced cardiac ischaemia 
Myocardial infarction 
Asymptomatic elevation in circulating troponin I levels 
VDA-induced haemodynamic changes 
Hypertension 
Hypotension 
VDA-induced perturbations in cardiac electrophysiology 
Transient QT prolongation 
Delayed ventricular repolarisation 
Tachycardia 
Bradycardia 
Atrial fibrillation 
Table 2: VDA-induced cardiac effects reported in preclinical and clinic studies 
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